

Freedom of Information Request: Our Reference CTMUHB_214_23

You asked:

1. For the 4 months from January to April 2023, how many patients received the following anti-VEGF treatments for any eye condition:

- **Aflibercept**
- **Bevacizumab**
- **Brolucizumab**
- **Dexamethasone**
- **Faricimab**
- **Ranibizumab**

Please find below a table populated with data that is available to Medicines Management for the period of January 23 to April 23, as requested.

Medicine	Number Administered
Aflibercept	1687
Bevacizumab	26
Brolucizumab	0
Dexamethasone	48
Faricimab	347
Ranibizumab Lucentis	- 10

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

- **Aflibercept**
- **Bevacizumab**
- **Brolucizumab**
- **Dexamethasone**
- **Faricimab**
- **Ranibizumab**

The level of information requested is not captured on our Medicines Management system. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl through all the Ophthalmology patients treated within this timeframe and would significantly exceed the 18 hours' time and £450 cost limit set out within Section 12 of the Freedom of Information Act.